⌕
Kymera Therapeutics · KYMR · Nasdaq
Tenet 41 · Weak
Compare
$121.52−3.44%At closeTenet 41 · Weak
$121.52−4.33 (−3.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kymera Therapeutics (KYMR) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

44 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 50% below its peak, net margin −794.0%. Worth your attention in FY25: Share count (+76.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼16.7%
39.2
FY21→FY25CAGR −14.3%/yr
Net income ($M)▼39.1%
−311.4
FY21→FY25CAGR —
Free cash flow ($M)▼13.0%
−234.3
FY21→FY25CAGR —
Diluted EPS▼23.8%
−3.69
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+76.1%

48.0mn → 84.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$1.4M

−88.7% YoY in FY25 · 3.7% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)39.2Revenue0.0COGS−316.6R&D−68.2SG&A−349.4Op income38.0Tax & other−311.4Net income

-794¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -794.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
102,236.039,211.047,072.078,592.046,826.072,832.0▼16.7%−14.3%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A72,832.0——
Research & development
429,983.0316,568.0240,248.0189,081.0164,248.0137,017.0▲31.8%+23.3%
Selling, general & admin
77,141.068,187.063,534.055,041.043,834.036,345.0▲7.3%+17.0%
Total operating expenses
507,124.0388,610.0308,707.0244,122.0208,082.0173,362.0▲25.9%+22.4%
Operating incomefeeds ROC rank
−404,888.0−349,399.0−261,635.0−165,530.0−161,256.0−100,530.0▼33.5%—
Other income, net
55,463.038,048.037,777.018,568.06,448.0313.0——
Pretax income
−349,425.0−311,351.0−223,858.0−146,962.0−154,808.0−100,217.0▼39.1%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−349,425.0−311,351.0−223,858.0−146,962.0−154,808.0−100,217.0▼39.1%—
Per share
Diluted EPSbuyback-sensitive
−3.63−3.69−2.98−2.52−2.87−2.09▼23.8%—
Diluted shares (mn)
100.1084.4975.0458.3753.9347.99▲12.6%+15.2%
Margins
Gross margin
—A—A—A—A—A100.0%——
Operating margin
−396.0%−891.1%−555.8%−210.6%−344.4%−138.0%▼335.3pp−753.0pp
Net margin5th pct in Healthcare
−341.8%−794.0%−475.6%−187.0%−330.6%−137.6%▼318.5pp−656.4pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Kymera Therapeutics' revenue last fiscal year?

Kymera Therapeutics reported revenue of $39.2M in fiscal 2025, down 16.7% from fiscal 2024.

What was Kymera Therapeutics' net income?

Kymera Therapeutics reported net income of −$311.4M in fiscal 2025, a net margin of −794.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.